Clinical trials of antiangiogenic therapy for hepatocellular carcinoma
Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular c...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2016-04, Vol.21 (2), p.213-218 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 218 |
|---|---|
| container_issue | 2 |
| container_start_page | 213 |
| container_title | International journal of clinical oncology |
| container_volume | 21 |
| creator | Taketomi, Akinobu |
| description | Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib. |
| doi_str_mv | 10.1007/s10147-016-0966-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1779883022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4014284171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-69e545e06a5dd0bd05706253e0ae12d5aff62107237f72eeb72eeb1503663fa3</originalsourceid><addsrcrecordid>eNp1kMFLwzAUxoMobk7_AC9S8OKl-pI0SXuU4VQYeNk9ZG2yZbRNTdrD_nuzdYoIXl4C7_d97-ND6BbDIwYQTwEDzkQKmKdQ8DjO0BRnVKRCCHIe_zTDacEJm6CrEHYAWHBGLtGE8LwoCMunaDGvbWtLVSe9t6oOiTOJanur2o11Gx1XSb_VXnX7xDifbHWnelfquh5q5ZNS-dK2rlHX6MJEtb45vTO0Wrys5m_p8uP1ff68TEta8D7lhWYZ08AVqypYV8AExHhUg9KYVEwZwwkGQagwgmi9Pg7MgHJOjaIz9DDadt59Djr0srHhkEa12g1BYiGKPKdASETv_6A7N_g2hjtSNONU0EjhkSq9C8FrIztvG-X3EoM8dCzHjmXsWB46lhA1dyfnYd3o6kfxXWoEyAiEuGo32v86_a_rF4r3hi4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779346373</pqid></control><display><type>article</type><title>Clinical trials of antiangiogenic therapy for hepatocellular carcinoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Taketomi, Akinobu</creator><creatorcontrib>Taketomi, Akinobu</creatorcontrib><description>Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-016-0966-0</identifier><identifier>PMID: 26899258</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Angiogenesis ; Angiogenesis Inhibitors - therapeutic use ; Cancer Research ; Cancer therapies ; Carcinoma, Hepatocellular - blood supply ; Carcinoma, Hepatocellular - drug therapy ; Clinical trials ; Clinical Trials as Topic ; Humans ; Invited Review Article ; Liver cancer ; Liver Neoplasms - blood supply ; Liver Neoplasms - drug therapy ; Medicine ; Medicine & Public Health ; Neovascularization, Pathologic - drug therapy ; Oncology ; Prognosis ; Surgical Oncology</subject><ispartof>International journal of clinical oncology, 2016-04, Vol.21 (2), p.213-218</ispartof><rights>Japan Society of Clinical Oncology 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-69e545e06a5dd0bd05706253e0ae12d5aff62107237f72eeb72eeb1503663fa3</citedby><cites>FETCH-LOGICAL-c396t-69e545e06a5dd0bd05706253e0ae12d5aff62107237f72eeb72eeb1503663fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-016-0966-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-016-0966-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26899258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taketomi, Akinobu</creatorcontrib><title>Clinical trials of antiangiogenic therapy for hepatocellular carcinoma</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - blood supply</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Invited Review Article</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - blood supply</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Surgical Oncology</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kMFLwzAUxoMobk7_AC9S8OKl-pI0SXuU4VQYeNk9ZG2yZbRNTdrD_nuzdYoIXl4C7_d97-ND6BbDIwYQTwEDzkQKmKdQ8DjO0BRnVKRCCHIe_zTDacEJm6CrEHYAWHBGLtGE8LwoCMunaDGvbWtLVSe9t6oOiTOJanur2o11Gx1XSb_VXnX7xDifbHWnelfquh5q5ZNS-dK2rlHX6MJEtb45vTO0Wrys5m_p8uP1ff68TEta8D7lhWYZ08AVqypYV8AExHhUg9KYVEwZwwkGQagwgmi9Pg7MgHJOjaIz9DDadt59Djr0srHhkEa12g1BYiGKPKdASETv_6A7N_g2hjtSNONU0EjhkSq9C8FrIztvG-X3EoM8dCzHjmXsWB46lhA1dyfnYd3o6kfxXWoEyAiEuGo32v86_a_rF4r3hi4</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Taketomi, Akinobu</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Clinical trials of antiangiogenic therapy for hepatocellular carcinoma</title><author>Taketomi, Akinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-69e545e06a5dd0bd05706253e0ae12d5aff62107237f72eeb72eeb1503663fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - blood supply</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Invited Review Article</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - blood supply</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taketomi, Akinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taketomi, Akinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical trials of antiangiogenic therapy for hepatocellular carcinoma</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>21</volume><issue>2</issue><spage>213</spage><epage>218</epage><pages>213-218</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>26899258</pmid><doi>10.1007/s10147-016-0966-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2016-04, Vol.21 (2), p.213-218 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1779883022 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Angiogenesis Angiogenesis Inhibitors - therapeutic use Cancer Research Cancer therapies Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - drug therapy Clinical trials Clinical Trials as Topic Humans Invited Review Article Liver cancer Liver Neoplasms - blood supply Liver Neoplasms - drug therapy Medicine Medicine & Public Health Neovascularization, Pathologic - drug therapy Oncology Prognosis Surgical Oncology |
| title | Clinical trials of antiangiogenic therapy for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A03%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20trials%20of%20antiangiogenic%20therapy%20for%20hepatocellular%20carcinoma&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Taketomi,%20Akinobu&rft.date=2016-04-01&rft.volume=21&rft.issue=2&rft.spage=213&rft.epage=218&rft.pages=213-218&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-016-0966-0&rft_dat=%3Cproquest_cross%3E4014284171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779346373&rft_id=info:pmid/26899258&rfr_iscdi=true |